CNBC August 13, 2025
Annika Kim Constantino, Ashley Capoot

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

A new program from the Trump administration aims to make setting up manufacturing plants in the U.S. less of a headache for the pharmaceutical industry.

The Food and Drug Administration on Thursday announced a new “PreCheck” program, which will use a two-phase approach to help boost domestic drug manufacturing after it shrunk dramatically over the past two decades.

The announcement is a direct response to President Donald Trump’s executive order in May calling on the FDA to reduce regulatory hurdles for domestic drug production in the U.S.. That order asked...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
FDA guidance eases wearables oversight. But experts have questions about what’s next.
AI Model FDA-Cleared to Triage 14 Conditions
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2)
FDA Updates Two Digital Health Final Guidance Documents
FDA in Flux — January 2026 Newsletter

Share Article